Shiqiong Zhou

Adjuvant anti-TIGIT plus anti-PD-1 in melanoma: A necessary failure that clarifies the path forward

The phase 3 KEYVIBE-010 trial investigated adjuvant vibostolimab (anti-TIGIT) plus pembrolizumab versus pembrolizumab alone in resected stage IIB–IV melanoma. At the first interim analysis, the combination met futility criteria, with a recurrence-free survival hazard ratio of 1.2...